Roche, Glaxo add psychiatric behavior warnings to flu drugs

03/5/2008 | Guardian (London), The

Roche Holding and GlaxoSmithKline PLC -- manufacturers of Tamiflu and Relenza, respectively -- have placed new warnings regarding delirium and abnormal psychiatric behavior on the labels of their influenza medications. The FDA has reviewed reports of neuropsychiatric problems in some patients, primarily in Japan. The drugmakers, however, said on the labels that their drugs' link to these adverse reactions "has not been established."

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Various Health Care and IT Positions
Centers for Medicare & Medicaid Services
Baltimore, Bethesda, MD
Principal, Global Compliance Operations
DJO Global
Vista, CA